



DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Lautt et al. Examiner: Unknown
Serial No.: 10/502,119 Group Art Unit: 1632
Filed: July 21, 2004 Docket: 14233.19USWO
Title: USE OF PHOSPHODIESTERASE ANTAGONISTS TO TREAT INSULIN RESISTANCE

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 May _____, 2005.

By: _____
Name: _____

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450




Sir:

We are transmitting herewith the attached:


- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 10 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
612.332.5300

By: 
Name: Ronald A. Daignault
Reg. No.: 25,968
RAD/BRD/mls

S/N 10/592,119



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lautt et al.	Examiner:	Unknown
Serial No.:	10/502,119	Group Art Unit:	1632
Filed:	July 21, 2004	Docket No.:	14233.19USWO
Title:	USE OF PHOSPHODIESTERASE ANTAGONISTS TO TREAT INSULIN RESISTANCE		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 May ____, 2005.

By: _____

Name: _____

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked


as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: 5/6/2005


Ronald A. Daignault
Reg. No. 25,968
RDaignault:BRD:mls



Date Mailed: May ____, 2005

Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 14233.19USWO	Application Number: 10/502,119
	Applicant: Lutt et al.	
	Filing Date: July 21, 2004	Group Art Unit: 1632

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	1 020 452	06/26/1998	EP				
	1 142 879	12/20/1999	EP				
	02/13798	02/21/2002	WO				
	02/24698	03/28/2002	WO				
	03/028730	04/10/2003	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Evans et al., (2001) "Insulin resistance and β -cell dysfunction as therapeutic targets in type 2 diabetes", <i>Diabetes, Obesity and Metabolism</i> , 3: 219-229.
		Lutt et al., (1998) "Rapid insulin sensitivity test (RIST)", <i>Can. J. Physiol. Pharmacol.</i> , 76: 1080-1086.
		Lutt (1999) "The HISS story overview: a novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetics" <i>Can. J. Physiol. Pharmacol.</i> , 77: 553-562.
		Nakaya et al. (1999) "Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM", <i>Diabetes, Obesity and Metabolism</i> , 1: 37-41.
		Petrie et al., (1996) "Endothelial Nitric Oxide Production and Insulin Sensitivity", <i>Circulation</i> , 93: 1331-1333.

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	